Evidence map›Paper›PMID 24966713›Full record

ReviewSubstance abuse and rehabilitation2014

Emerging drugs of abuse: current perspectives on substituted cathinones.

Magalie Paillet-Loilier, Alexandre Cesbron, Reynald Le Boisselier, Joanna Bourgine, Danièle Debruyne

Open access · goldAbstract readReview
In one paragraph

Review in Substance abuse and rehabilitation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. PSAnalytical chemistry · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. An updated review on synthetic cathinones.Archives of toxicology · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Magalie Paillet-LoilierToxicology and Pharmacology Laboratory, University Hospital Centre, Caen, France.
Alexandre CesbronToxicology and Pharmacology Laboratory, University Hospital Centre, Caen, France.
Reynald Le BoisselierCentre d'Evaluation et d'Information sur la Pharmacodépendance - Addictovigilance (CEIP-A), Department of Pharmacology, University Hospital Centre, Caen, France.
Joanna BourgineToxicology and Pharmacology Laboratory, University Hospital Centre, Caen, France.
Danièle DebruyneToxicology and Pharmacology Laboratory, University Hospital Centre, Caen, France ; Centre d'Evaluation et d'Information sur la Pharmacodépendance - Addictovigilance (CEIP-A), Department of Pharmacology, University Hospital Centre, Caen, France.
Groupe de Recherche sur l'Alcool et les Pharmacodépendances · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Substituted cathinones are synthetic analogs of cathinone that can be considered as derivatives of phenethylamines with a beta-keto group on the side chain. They appeared in the recreational drug market in the mid-2000s and now represent a large class of new popular drugs of abuse. Initially considered as legal highs, their legal status is variable by country and is rapidly changing, with government institutions encouraging their control. Some cathinones (such as diethylpropion or pyrovalerone) have been used in a medical setting and bupropion is actually indicated for smoking cessation. Substituted cathinones are widely available from internet websites, retail shops, and street dealers. They can be sold under chemical, evocative or generic names, making their identification difficult. Fortunately, analytical methods have been developed in recent years to solve this problem. Available as powders, substituted cathinones are self-administered by snorting, oral injestion, or intravenous injection. They act as central nervous system stimulants by causing the release of catecholamines (dopamine, noradrenaline, and serotonin) and blocking their reuptake in the central and peripheral nervous system. They may also decrease dopamine and serotonin transporter function as nonselective substrates or potent blockers and may inhibit monoamine oxidase effects. Nevertheless, considerable differences have been found in the potencies of the different substituted cathinones in vitro. Desired effects reported by users include increased energy, empathy, and improved libido. Cardiovascular (tachycardia, hypertension) and psychiatric/neurological signs/symptoms (agitation, seizures, paranoia, and hallucinations) are the most common adverse effects reported. Severe toxicity signs compatible with excessive serotonin activity, such as hyperthermia, metabolic acidosis, and prolonged rhabdomyolysis, have also been observed. Reinforcing potential observed in animals predicts a high potential for addiction and abuse in users. In case of overdose, no specific antidote exists and no curative treatment has been approved by health authorities. Therefore, management of acute toxic effects is mainly extrapolated from experience with cocaine/amphetamines.

Indexed as

analysischemistrydependencemedical carepharmacologysubstituted cathinonestoxicology

Identifiers

PMID24966713
PMCPMC4043811
OpenAlexW2086202911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.